• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PAVmed Inc. (Amendment)

    10/6/21 2:28:49 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email
    SC 13G/A 1 form_sc13ga.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 4)*
     
    PAVmed Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    70387R106
    (CUSIP Number)
     
    October 4, 2021
    (Date of Event which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.: 70387R106
     
     
     
     
     
    1
    NAME OF REPORTING PERSON
     
    Matthew Sirovich
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)  [   ]
    (b)  [   ]
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    2,504,244
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    2,504,244
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,504,244
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    2.9%
    12
    TYPE OF REPORTING PERSON
     
    IN




    CUSIP No.: 70387R106
     
     
     
     
    ITEM 1(a).
    NAME OF ISSUER:
     
     
     
    PAVmed Inc. (the “Issuer”)
     
     
    ITEM 1(b).
    ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
     
     
     
    One Grand Central Plaza
    Suite 4600
    60 E. 42nd Street
    New York, NY 10165
     
     
    ITEM 2(a).
    NAME OF PERSON FILING:
     
     
     
    Matthew Sirovich
     
     
    ITEM 2(b).
    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
     
     
     
    c/o Scopia Capital Management LP
    152 West 57th Street, 33rd Floor
    New York, NY 10019
     
     
    ITEM 2(c).
    CITIZENSHIP:
     
     
     
    United States
     
     
    ITEM 2(d).
    TITLE OF CLASS OF SECURITIES:
     
     
     
    Common Stock, par value $0.001 per share (“Common Stock”)
     
     
    ITEM 2(e).
    CUSIP NUMBER:
     
     
     
    70387R106
     
    ITEM 3.
    IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
     
     
     
    Not Applicable.


     
     
    ITEM 4.
    OWNERSHIP:
     
     
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
     
     
    (a)
    Amount beneficially owned:
     
     
    2,504,244
     
     
     
     
    (b)
    Percent of class:
     
     
    2.9%
     
     
     
     
    (c)
    Number of shares as to which the person has:
     
     
     
     
     
    (i)        Sole power to vote or to direct the vote:

     
     
    2,504,244
     
     
     
     
     
    (ii)       Shared power to vote or to direct the vote:
     
     
    0
     
     
     
     
     
    (iii)      Sole power to dispose or to direct the disposition of:
     
     
    2,504,244
     
     
     
     
     
    (iv)      Shared power to dispose or to direct the disposition of:
     
     
    0
     

    Of the shares of Common Stock reported as beneficially owned herein, The Sirovich Family Charitable Foundation (the “Sirovich Foundation”) directly holds 1,560,338 shares of Common Stock.  Matthew Sirovich is a Director and President of the Sirovich Foundation and may be deemed to beneficially own the shares of Common Stock held by the Sirovich Foundation.  In addition, The Boomer Fund, L.P. (“Boomer”) directly holds 466,000 shares of Common Stock.  Mr. Sirovich is the general partner of Boomer and may be deemed to beneficially own the shares of Common Stock held by Boomer.  Mr. Sirovich directly holds and beneficially owns 477,906 shares of Common Stock.  As of December 31, 2020, Mr. Sirovich also held Series Z Warrants to purchase 458,257 shares of Common Stock and may have been deemed to beneficially own the 857,452 shares of Common Stock underlying the Series Z Warrants held by the Sirovich Foundation and 466,000 shares of Common Stock underlying the Series Z Warrants held by Boomer.  The Series Z Warrants were exercisable upon issuance for an exercise price of $1.60 per share of Common Stock and were set to expire on April 30, 2024. All such Series Z Warrants held by Mr. Sirovich, the Sirovich Foundation and Boomer have been exercised in full for shares of Common Stock.  The percentage of beneficial ownership reported herein is based on 84,767,593 shares of Common Stock outstanding as of August 12, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 16, 2021, plus 1,781,709 shares of Common Stock received upon the exercise of the Series Z Warrants.
     


    ITEM 5.
    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
     
     
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
     
     
    ITEM 6.
    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
     
     
     
    The information in Item 4 is incorporated herein by reference.
     
     
    ITEM 7.
    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
     
     
     
    Not applicable.
     
     
    ITEM 8.
    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

     
     
     
    Not applicable.
     
    ITEM 9.
    NOTICE OF DISSOLUTION OF GROUP:
     
     
     
    Not applicable.
     
     
    ITEM 10.
    CERTIFICATION:
     
     
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.




    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:  October 6, 2021
     
    /s/ Matthew Sirovich
    MATTHEW SIROVICH
     
     



    Get the next $PAVM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    SEC Filings

    See more
    • PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/24/25 8:15:29 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/18/25 5:00:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.

      SCHEDULE 13G/A - PAVmed Inc. (0001624326) (Subject)

      5/15/25 1:14:39 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on PAVmed with a new price target

      Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

      3/30/21 6:22:24 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lake Street Capital reiterated coverage on PAVmed with a new price target

      Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

      2/22/21 4:33:18 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

      Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK, June 24, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ("Veris"), today announced the completion of a private placement equity financing directly into Veris, yielding $2.5 million in proceeds (gross and net). This supplements a prior $2.4 million financing completed earlier this year.

      6/24/25 8:01:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

      Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, prim

      6/18/25 12:02:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

      Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Ca

      6/3/25 8:31:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

      3 - PAVmed Inc. (0001624326) (Issuer)

      3/14/25 7:53:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      10/23/24 4:36:47 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Agrawal Sundeep

      4 - PAVmed Inc. (0001624326) (Issuer)

      9/20/24 4:13:39 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

      NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

      5/27/25 7:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Financials

    Live finance-specific insights

    See more
    • PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

      Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

      5/15/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      9/23/24 8:46:15 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      2/14/24 3:38:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care